NADOLOL Drug Patent Profile
✉ Email this page to a colleague
When do Nadolol patents expire, and when can generic versions of Nadolol launch?
Nadolol is a drug marketed by Alembic, Amneal Pharms Co, Aurobindo Pharma, Beximco Pharms Usa, Chartwell Rx, Heritage Pharma, Invagen Pharms, Novast Labs, Rising, Rk Pharma, Sandoz, Teva Pharms, Zydus Pharms, Impax Labs, and Mylan. and is included in sixteen NDAs.
The generic ingredient in NADOLOL is bendroflumethiazide; nadolol. There are four drug master file entries for this compound. Additional details are available on the bendroflumethiazide; nadolol profile page.
Summary for NADOLOL
| US Patents: | 0 |
| Applicants: | 15 |
| NDAs: | 16 |
| Finished Product Suppliers / Packagers: | 16 |
| Raw Ingredient (Bulk) Api Vendors: | 59 |
| Clinical Trials: | 23 |
| Patent Applications: | 5,338 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for NADOLOL |
| Drug Sales Revenues: | Drug sales revenues for NADOLOL |
| What excipients (inactive ingredients) are in NADOLOL? | NADOLOL excipients list |
| DailyMed Link: | NADOLOL at DailyMed |
Recent Clinical Trials for NADOLOL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Unity Health Toronto | N/A |
| National Institute on Aging (NIA) | Phase 4 |
| The New York Community Trust | Phase 4 |
Pharmacology for NADOLOL
| Drug Class | beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
Medical Subject Heading (MeSH) Categories for NADOLOL
Anatomical Therapeutic Chemical (ATC) Classes for NADOLOL
US Patents and Regulatory Information for NADOLOL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zydus Pharms | NADOLOL | nadolol | TABLET;ORAL | 207761-003 | Jul 28, 2017 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Rk Pharma | NADOLOL | nadolol | TABLET;ORAL | 212856-003 | Sep 13, 2019 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Mylan | NADOLOL AND BENDROFLUMETHIAZIDE | bendroflumethiazide; nadolol | TABLET;ORAL | 078688-002 | Feb 15, 2008 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Rising | NADOLOL | nadolol | TABLET;ORAL | 074172-002 | Oct 31, 1993 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Sandoz | NADOLOL | nadolol | TABLET;ORAL | 074501-001 | Nov 9, 1995 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
